Genotype linked to shorter survival in metastatic prostate cancer - Urology Times

-

Inheriting the adrenal-permissive HSD3B1(1245C) genotype is associated with worse outcomes in low-volume metastatic prostate cancer and might someday help identify patients who could benefit from escalated therapy, according to a recent study.

In essence, some patients are genetically predisposed to having their prostate cancers make their own potent androgens, such as testosterone or dihydrotestosterone (DHT), from non-testicular sources, according to study author Nima Sharifi, MD, of Cleveland Clinic Genitourinary Malignancies Research Center, Cleveland.

“This comes from germline inheritance of an effectively ‘fast’ enzyme by the gene HSD3B1 that allows for prostate cancer to make these androgens. What this means clinically is that men with low-volume metastatic prostate cancer who inherit this fast form of HSD3B1 treated with medical or surgical castration progress more quickly and have shorter survival compared with men who do not inherit this fast enzyme,” Dr. Sharifi said.

Read: Hypofractionation noninferior to conventional fractionation for localized PCa

Development of castration-resistant prostate cancer is driven in large part to the tumor’s capability of converting nongonadal or extragonadal precursor steroids. While the adrenal-permissive HSD3B1 (1245C) allele augments extragonadal DHT synthesis, the adrenal-restrictive allele limits extragonadal DHT synthesis, according to Dr. Sharifi.

The adrenal permissive allele is common, occurring with about 35% frequency in Caucasians, meaning one in two men will harbor at least one allele copy. It is most common in people of European descent and tends to be less common in people of African and East Asian descent, Dr. Sharifi said.

The study, published in JAMA Oncology (Feb. 13, 2020 [Epub ahead of print]), looks at germline data from 475 Caucasian men in the Chemo-hormonal Therapy versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer (CHAARTED) clinical trial. CHAARTED was a phase III study in which researchers randomized men with metastatic castration-sensitive prostate cancer to castration versus castration plus docetaxel (Taxotere).

“Our current study is a validation in a phase III clinical trial of men who received castration versus castration plus docetaxel chemotherapy. It is the first clinical trial level validation and builds upon our initial discovery in the laboratory and several retrospective clinical studies that determined poor clinical outcomes in men with adrenal-permissive HSD3B1 genetics,” Dr. Sharifi said.

Dr. Sharifi and colleagues found that freedom from castration-resistant prostate cancer at 2 years for men with low-volume disease was 51% for the adrenal-permissive genotype versus 70.5% in men with low-volume disease and the adrenal-restrictive genotype.

Continue to the next page for more



Comments

Post a Comment

Popular posts from this blog

Expert Discusses Data From First Positive Trial for PARP Inhibitor in Prostate Cancer - Targeted Oncology

-
Image
Alan Bryce, MD PARP inhibition with olaparib (Lynparza) improved radiographic progression-free survival (rPFS) in heavily pretreated patients with metastatic castration-resistant prostate cancer (mCRPC) who had alterations in homologous recombination repair (HRR) genes, according to findings from the phase III PROfound trial presented at the 2019 ESMO Congress. This was the first positive randomized phase III trial reported evaluating a PARP inhibitor in men with mCRPC. The PROfound trial enrolled patients to 2 cohorts. In cohort A, 245 patients with  BRCA1/2  or  ATM  alterations, markers of HRR, were randomized 2:1 to receive either olaparib (n = 162) or physician’s choice of abiraterone acetate (Zytiga) with prednisone or enzalutamide (Xtandi) (n = 83). In cohort B, 142 patients with alterations in the  BARD1, BRIP1, CDK12, CHEK1/2, FANCL, PALB2, PPP2R2A, RAD51B/C/D , or  RAD54L , all of which are associated with HRR indirectly, were also randomized 2:...
Read more

Sentinel lymph node biopsy: What cancer patients should know

-
Image
cancer lump on neck :: Article Creator Doctor Watching TV Show Spotted Cancer On Show's Guest That She Didn't Know About Say what you will about social media and daytime TV, but sometimes, they can help work wonders. In fact, the power of Facebook and the popularity of HGTV's Beachfront Bargain Hunt played a big part in helping Nicole McGuiness get ahead of her serious cancer diagnosis - but it was an eagle-eyed doctor who really saved her bacon. The then-32-year-old appeared on the property series alongside her father while in search of a holiday home in North Carolina to celebrate her recent recovery from brain cancer in May 2018. She explained that she had set her sights on 'something near the water', specifically a beachfront property in Morehead City, to start afresh in this new phase of her life. Dr. Erich Voigt was one of the viewers who tuned into the Beachfront Bargain Hunt episode, which Nicole featured in, an...
Read more

Lymph node metastasis in cancer progression: molecular mechanisms, clinical significance and therapeutic interventions

-
Image
common sign of prostate cancer :: Article Creator Seven Early Warning Signs Of Killer Silent Cancer - All Men Need To Know Prostate cancer is the most common cancer among males in the UK but not everybody knows about the symptoms to look out for - here are seven early warning signs Prostate cancer is the most common cancer among men in the UK ( Image: Getty Images) Thousands of men across the UK are diagnosed with prostate cancer every year. It is the most common cancer among males so it is vitally important for men to know the signs of prostate cancer and how to check for it. According to Cancer Research UK, there are around 55,100 new prostate cancer cases in the UK every year, which is roughly 150 every day. Sadly, there are around 12,000 prostate cancer deaths in the UK every year, an average of 33 a day. Older men are far more susceptible to getting prostate cancer. Between 2017-2098, 34 per cent of diagnosed cases were m...
Read more